Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03FUG
|
|||
| Former ID |
DIB011924
|
|||
| Drug Name |
Pegylated carboxyhemoglobin
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57.0; ICD-9: 282.6] | Phase 2 | [1] | |
| Company |
Sangart
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01925001) Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.